Skip to main content
Laura Dichtel, MD, Endocrinology, Boston, MA

LauraDichtelMD

Endocrinology • Boston, MA

Diabetes, Lipid Metabolism, Pituitary Disorders & Neuroendocrinology

Instructor In Medicine, Harvard Medical School and Assistant in Medicine, Massachusetts General Hospital

Join to view full profile

Dr. Dichtel is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

  • Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
  • Connect with colleagues in the same hospital or clinic.
  • Read the latest clinical news, personalized to your specialty.

See Dr. Dichtel's full profile

Already have an account?

  • Office

    55 Fruit St
    # BUL457
    Boston, MA 02114
    Phone+1 617-724-3614
    Fax+1 617-726-5072

Education & Training

  • Massachusetts General Hospital
    Massachusetts General HospitalFellowship, Endocrinology, Diabetes, and Metabolism, 2012 - 2015
  • Brigham and Women's Hospital
    Brigham and Women's HospitalResidency, Internal Medicine, 2009 - 2012
  • Yale School of Medicine
    Yale School of MedicineClass of 2009

Certifications & Licensure

  • MA State Medical License
    MA State Medical License 2012 - 2025
  • American Board of Internal Medicine Internal Medicine
  • American Board of Internal Medicine Endocrinology, Diabetes and Metabolism

Clinical Trials

Publications & Presentations

PubMed

Lectures

  • Neuroendocrinology and Pituitary 
    ENDO 2019 - New Orleans, LA - 3/25/2019
  • Optimizing Hormone Treatment in the Hypopituitary Patient (Repeat) 
    ENDO 2019 - New Orleans, LA - 3/25/2019
  • Optimizing Hormone Treatment in the Hypopituitary Patient 
    ENDO 2019 - New Orleans, LA - 3/25/2019

Press Mentions

  • Top in Endocrinology: Nonalcoholic Fatty Liver Disease in Patients with Obesity, Diabetes
    Top in Endocrinology: Nonalcoholic Fatty Liver Disease in Patients with Obesity, DiabetesJune 29th, 2022
  • Lumos Pharma, Inc. (LUMO) CEO Richard Hawkins on Q1 2022 Results - Earnings Call Transcript
    Lumos Pharma, Inc. (LUMO) CEO Richard Hawkins on Q1 2022 Results - Earnings Call TranscriptMay 11th, 2022
  • Lumos Pharma Announces a Clinical Collaboration with Massachusetts General Hospital (MGH) to Evaluate Oral LUM-201 in Nonalcoholic Fatty Liver Disease (NAFLD) in a Phase 2 Investigator-Initiated Trial
    Lumos Pharma Announces a Clinical Collaboration with Massachusetts General Hospital (MGH) to Evaluate Oral LUM-201 in Nonalcoholic Fatty Liver Disease (NAFLD) in a Phase 2 Investigator-Initiated TrialMay 5th, 2022
  • Join now to see all

Professional Memberships

Dr. Laura Dichtel, Dr. Laura Dichtel, MD, Dr. L Dichtel